Intestinal barrier defenses and MyD88 are impaired in diabetes and ICAM and FMO3 expression induced while AhR ligands reverse diabetes-induced intestinal barrier damage, insulin insensitivity, FMO3/ICAM expression and systemic inflammation (Liu W. C. et al., 2020). Here, MYD88 is linked to diabetes mellitus.